Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Msci Inc (MSCI): ValueAct’s CEO Jeff Ubben Pushes for Board Seats; Says Has “Unanswered Questions”

In a new filing with the Securities and Exchange Commission, Jeff Ubben‘s ValueAct Capital has disclosed a letter sent to the Lead Director of the application software company Msci Inc (NYSE:MSCI) Rodolphe M. Vallee in which Mr. Ubben expressed his frustration with the board not proceeding with the fund’s request to appoint their representatives. ValueAct has been a long-term shareholder of MSCI, holding 9.31 million shares, which represent 8.3% of the company’s common stock.


ValueAct is a large hedge fund with more than $14 billion in equity portfolio. It was founded by a former Managing Partner of Richard Blum’s Blum Capital Partners Jeff Ubben, who for more than a decade has been the Chief Executive Officer and Chief Investment Officer of the company. ValueAct invests in companies that have high-quality businesses and usually pursues representation on the companies’ boards. Overall, over the last years, ValueAct has appointed his representatives on the board of 30 companies, including Microsoft Corporation (NASDAQ:MSFT) and Valeant Pharmaceuticals Intl Inc (NYSE:VRX) among others.

The fund usually manages a concentrated equity portfolio with around 15 positions and has a slight focus towards the technology sector. The average holding period for each position is approximately three years. This strategy has proved to be effective so far, as we can observe from ValueAct’s latest moves. Of late, the investor has been trimming its position in another application software company (where it also has a representative on the board), Adobe Systems Incorporated (NASDAQ:ADBE), while the stock more than doubled in value since it was added to ValueAct’s 13F portfolio. In addition, a couple of months ago, the fund sold some 3.39 million shares of Rockwell Collins, Inc. (NYSE:COL), trimming its stake to 7.80 million shares, equal to 5.8% of the company; Rockwell is another long-term investment, whose stock gained around 80% since ValueAct initiated its stake.

Msci Inc (NYSE:MSCI) has been in ValueAct’s equity portfolio for more than two years and the fund has raised its stake from 6.16 million shares it held initially, in October 2012. Meanwhile, the stock gained around 32% since then, as the $5.3 billion company reported solid revenue and profit growth in the last couple of years.

In his letter, Mr. Ubben said that ValueAct has first asked for representatives on Msci Inc (NYSE:MSCI)’s board in August 2014, on the back of several unanswered questions regarding the company’s strategy and organization. The investor mentioned that the company’s Risk Management Analytics and Portfolio Management Analytics segments have a great potential and strong competitive positions, but they have not show a significant market share growth.

“And as the index business continues to grow at a double digit rate, with its attendant high incremental margin, we cannot understand where all the money is going?” the letter added.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.